Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Clindamycin phosphate and benzoyl peroxide

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Clindamycin phosphate and benzoyl peroxide key facts

Used for
Clindamycin and Benzoyl Peroxide Gel is indicated for the topical treatment of acne vulgaris. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
Yes
Typical pharmacy cost
$0.4163–$2.18 per gram (benzoyl peroxide 5% · clindamycin phosphate 1%; NADAC)
Latest FDA recall
December 28, 2016 (Class II)

Sources: FDA label (January 31, 2026); FDA NDC Directory (October 30, 2026); CMS NADAC (November 4, 2026); FDA enforcement reports (October 27, 2026). Not medical advice.

Quick answers

What is Clindamycin phosphate and benzoyl peroxide used for?
The FDA-approved label (Clindamycin and Benzoyl Peroxide, Glenmark Pharmaceuticals Inc., USA, January 31, 2026) says: “Clindamycin and Benzoyl Peroxide Gel is indicated for the topical treatment of acne vulgaris.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Clindamycin phosphate and benzoyl peroxide?
The “Adverse Reactions” section of the FDA label (Clindamycin and Benzoyl Peroxide, Glenmark Pharmaceuticals Inc., USA, January 31, 2026) begins: “During clinical trials, the most frequently reported adverse event in the clindamycin and benzoyl peroxide gel treatment group was dry skin (12%). The Table below lists local adverse events reported by at least 1% of patients in the clindamycin and benzoyl peroxide gel and vehicle groups.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Clindamycin phosphate and benzoyl peroxide have a boxed warning?
No. None of the 22 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Clindamycin phosphate and benzoyl peroxide?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Clindamycin phosphate and benzoyl peroxide been recalled?
FDA enforcement reports list 2 recalls of products of this medicine; the newest started December 28, 2016 (Class II). A recall usually concerns specific lots, not every product.
Who makes Clindamycin phosphate and benzoyl peroxide?
13 companies list prescription products of Clindamycin phosphate and benzoyl peroxide in the FDA NDC Directory, including Bryant Ranch Prepack, Sun Pharmaceutical Industries, Inc. and Padagis Israel Pharmaceuticals Ltd.

What Clindamycin phosphate and benzoyl peroxide is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Clindamycin and Benzoyl Peroxide Gel is indicated for the topical treatment of acne vulgaris.

— FDA label: Clindamycin and Benzoyl Peroxide, Glenmark Pharmaceuticals Inc., USA, effective January 31, 2026. Read the full label on DailyMed →

Label quoted: the one for the most common form (gel, topical), Clindamycin and Benzoyl Peroxide, Glenmark Pharmaceuticals Inc., USA; it covers 2 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 22 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 22 FDA labels for this medicine have a boxed warning.

Clindamycin phosphate and benzoyl peroxide side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

During clinical trials, the most frequently reported adverse event in the clindamycin and benzoyl peroxide gel treatment group was dry skin (12%). The Table below lists local adverse events reported by at least 1% of patients in the clindamycin and benzoyl peroxide gel and vehicle groups.

Read more of this section

Local Adverse Events – all causalities in >/= 1% of patients Clindamycin and Benzoyl Peroxide n=420 Vehicle n=168 Application site reaction 13 (3%) 1 (<1%) Dry skin 50 (12%) 10 (6%) Pruritus 8 (2%) 1 (<1%) Peeling 9 (2%) - Erythema 6 (1%) 1 (<1%) Sunburn 5 (1%) - The actual incidence of dry skin might have been greater were it not for the use of a moisturizer in these studies. Anaphylaxis, as well as allergic reactions leading to hospitalization, have been reported during post-marketing use of clindamycin/benzoyl peroxide products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

— FDA label: Clindamycin and Benzoyl Peroxide, Glenmark Pharmaceuticals Inc., USA, effective January 31, 2026. This is part of the section. Read the full label on DailyMed →

Clindamycin phosphate and benzoyl peroxide dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

Clindamycin and Benzoyl Peroxide Gel should be applied twice daily, morning and evening, or as directed by a physician, to affected areas after the skin is gently washed, rinsed with warm water and patted dry.

— FDA label: Clindamycin and Benzoyl Peroxide, Glenmark Pharmaceuticals Inc., USA, effective January 31, 2026. Read the full label on DailyMed →

Clindamycin phosphate and benzoyl peroxide in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Teratogenic Effects: Animal reproductive/developmental toxicity studies have not been conducted with clindamycin and benzoyl peroxide gel or benzoyl peroxide.

Read more of this section

Developmental toxicity studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (240 and 120 times amount of clindamycin in the highest recommended adult human dose based on mg/m 2, respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (100 and 50 times the amount of clindamycin in the highest recommended adult human dose based on mg/m 2, respectively) revealed no evidence of teratogenicity. There are no well-controlled trials in pregnant women treated with Clindamycin and Benzoyl Peroxide Gel. It also is not known whether Clindamycin and Benzoyl Peroxide Gel can cause fetal harm when administered to a pregnant woman.

— FDA label: Clindamycin and Benzoyl Peroxide, Glenmark Pharmaceuticals Inc., USA, effective January 31, 2026. Read the full label on DailyMed →

Clindamycin phosphate and benzoyl peroxide and breastfeeding

Quoted from the nursing mothers / lactation part of the FDA-approved label.

Nursing Women: It is not known whether Clindamycin and Benzoyl Peroxide Gel is excreted in human milk after topical application. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

— FDA label: Clindamycin and Benzoyl Peroxide, Glenmark Pharmaceuticals Inc., USA, effective January 31, 2026. Read the full label on DailyMed →

When Clindamycin phosphate and benzoyl peroxide should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

Clindamycin and Benzoyl Peroxide Gel is contraindicated in those individuals who have shown hypersensitivity to any of its components or to lincomycin. It is also contraindicated in those having a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

— FDA label: Clindamycin and Benzoyl Peroxide, Glenmark Pharmaceuticals Inc., USA, effective January 31, 2026. Read the full label on DailyMed →

Forms and how it is given

Dosage formsGel
RouteTopical
Prescription products25 in the FDA NDC Directory
Brand namesOnexton, Acanya, Neuac

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Clindamycin phosphate and benzoyl peroxide, by strength and form
Strength and formGeneric or brandPharmacies pay
benzoyl peroxide 2.5% · clindamycin phosphate 1%
gel
Generic $0.9098 per gram
benzoyl peroxide 3.75% · clindamycin phosphate 1%
gel
Generic $2.18 per gram
benzoyl peroxide 5% · clindamycin phosphate 1%
gel
Generic $0.4163–$2.18 per gram
12 packages, lowest to highest

NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA050819
ACANYA, ONEXTON
BauschOctober 23, 2008 13, latest July 11, 2025
2025: Manufacturing (CMC) · 2020: Labeling · 2020: Labeling

Generic approvals (10)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.

  1. December 28, 2016 · Class II · Terminated · D-0434-2017

    Microbial Contamination of Non-Sterile Product; small number of tubes may include the presence of mold on the cap

    Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/5%, 45 g tubes, Rx Only, Manufactured by Perrigo, Yeruham, Israel, Distributed by Perrigo, Allegan, MI --- NDC 45802-736-84, UPC 345802736840 — L. Perrigo Company

  2. September 20, 2013 · Class III · Terminated · D-020-2014

    Labeling: Incorrect or Missing Lot and/or Exp Date: This recall is being carried out due to an incorrect expiration date assigned to a lot of physicians samples.

    Acanya (Clindamycin Phosphate and Benzoyl Peroxide) Gel 1.2% and 2.5%, Net Wt. 3.5 g, Rx Only, Sample - not for sale, CORIA Laboratories, a division of Valeant Pharmaceuticals LLC, Bridgewater, NJ 08807 --- NDC 13548-132 — Valeant Pharmaceuticals North Am

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Official identifiers

RxCUI (RxNorm)358917, 885131, 1540241, 1540246, 1598470, 1598826
SPL set ID of the quoted label76795d1b-e1f2-4d1d-b42a-f1d4448c63c0
FDA labels (SPL)22
FDA applicationsNDA050819, 10 ANDA
Active ingredients (FDA)BENZOYL PEROXIDE / CLINDAMYCIN

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Clindamycin and Benzoyl Peroxide, Glenmark Pharmaceuticals Inc., USA, effective January 31, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers